Eyeworld Supplements

The pursuit of innovation Shire is a leading biotech with a global track record of success. T he company has a 30-year history of developing innova- tive medicines in specific therapeutic areas for patients with rare diseases and specialty conditions. With more than 5,000 employees—1,000 of whom are dedicated solely to research—commitment to a strong R&D strategy is at the core of the company, and is the basis for its ability to consistently deliver results. Shire's products are marketed in more than 50 countries, in diverse therapeutic areas, such as rare diseases, neurosci- ence, gastrointestinal diseases, and internal medicine. In May 2014, Shire established an Ophthalmics Business Unit as part of the company's commitment to developing innovative medicines for rare diseases and other specialty conditions where there is significant unmet patient need. Shire believes that eye health is an important factor to overall health and wellness at every stage of life. It is also clear that significant unmet treatment needs exist in this space. Introducing Shire in Ophthalmics The pursuit of innovation In just over one year, the company has made remarkable progress, having brought together a dedicated and experi- enced team of experts in ophthalmics and developed a robust pipeline through a combination of strategic acquisitions and organic growth. The company continues its focus on pursuing promising treatment options for rare eye diseases as well as those for anterior and posterior eye conditions. People, pipeline, products, and promise Shire's vision in Ophthalmics is focused on four critical success factors: • People • Pipeline of therapeutic candidates • Products that will deliver innovation and meet unmet needs • Promise to the eyecare community People O ver the last 18 months, Shire has brought together a strong leadership team with significant depth of expertise in ophthalmic medicine. The current team has more than 100 years of combined eyecare experience, and the company continues to invest, hiring high-caliber talent with ophthalmic experience for both R&D and commercial operations. Shire's approach to the development of the Ophthalmics unit is to leverage a biotech and entrepreneurial spirit, with the resources more typical of a larger company. As a result, the company has hired professionals who are exceptionally entrepreneurial in their outlook, committed to launching new products to meet unmet needs, and deter- mined to make a difference. The Ophthalmics team embodies a start-up mentality that is helping Shire to not just focus on its goals, but to achieve them in record time. " Ophthalmics is a new business unit at Shire, and the way we're building it is aligned with our aspiration to become a leading biotech company. We are investing significantly in research and development, aiming to bring innovation to the market. By focusing on our understanding of the needs of patients and physicians, we believe we can deliver against enormous unmet need in this area." Perry Sternberg, SVP and Head, Neuroscience and Ophthalmics Business Units, U.S. Rare Diseases and Commercial Excellence 2

• Cover